Activity Overview
This educational activity is an archive of the live presentation held on May 30, 2026.
For more information about this educational activity, the faculty,
and disclosures, please click here.
Target Audience
This educational activity is directed toward medical, surgical,
and radiation oncologists; advanced practitioners; nurses; pharmacists; and
other health care providers involved in the management of hepatobiliary
cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical evidence on the safety and efficacy of new immunotherapy approaches for the treatment of hepatobiliary cancers across diverse patient populations
- Integrate the latest evidence and expert guidance into personalized treatment plans for patients with hepatocellular and biliary tract cancers
- Apply multidisciplinary best practices to optimize coordination, continuity, and quality of care for patients with hepatobiliary cancers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
PER® is proud to partner with the Cholangiocarcinoma Foundation.
